SAB Biotherapeutics, Inc. (NASDAQ:SABS) Given Average Rating of “Moderate Buy” by Brokerages

Shares of SAB Biotherapeutics, Inc. (NASDAQ:SABS) have earned an average rating of “Moderate Buy” from the eleven analysts that are presently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and nine have given a buy recommendation to the company. The average 12-month target price among analysts that have covered the stock in the last year is $12.00.

SABS has been the topic of a number of research analyst reports. Leerink Partners increased their price objective on shares of SAB Biotherapeutics from $7.00 to $12.00 and gave the company an “outperform” rating in a research report on Monday, June 15th. Zacks Research upgraded shares of SAB Biotherapeutics from a “strong sell” rating to a “hold” rating in a research note on Monday, May 11th. Rodman & Renshaw reissued a “buy” rating and set a $13.00 price target on shares of SAB Biotherapeutics in a report on Monday, May 11th. HC Wainwright restated a “buy” rating and issued a $10.00 price target on shares of SAB Biotherapeutics in a research note on Monday, June 15th. Finally, Citigroup assumed coverage on SAB Biotherapeutics in a report on Friday, May 22nd. They issued a “buy” rating and a $11.00 price objective for the company.

SAB Biotherapeutics Price Performance

SABS opened at $3.66 on Friday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 11.45 and a current ratio of 11.45. The stock has a market capitalization of $279.84 million, a P/E ratio of -1.73 and a beta of 0.52. The company’s 50-day simple moving average is $3.72 and its two-hundred day simple moving average is $3.85. SAB Biotherapeutics has a 52-week low of $1.85 and a 52-week high of $6.60.

SAB Biotherapeutics (NASDAQ:SABS) last announced its quarterly earnings results on Tuesday, May 12th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.15). As a group, analysts predict that SAB Biotherapeutics will post -1.19 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. PNC Financial Services Group Inc. bought a new stake in shares of SAB Biotherapeutics during the 1st quarter valued at about $29,000. ADAR1 Capital Management LLC purchased a new stake in shares of SAB Biotherapeutics during the 3rd quarter valued at about $30,000. Dimensional Fund Advisors LP bought a new position in shares of SAB Biotherapeutics in the 3rd quarter worth approximately $32,000. State of Wyoming bought a new position in shares of SAB Biotherapeutics in the 4th quarter worth approximately $34,000. Finally, Virtu Financial LLC purchased a new position in shares of SAB Biotherapeutics in the third quarter worth approximately $40,000. 7.82% of the stock is owned by hedge funds and other institutional investors.

About SAB Biotherapeutics

SAB Biotherapeutics, Inc is a clinical-stage biotechnology company headquartered in Sioux Falls, South Dakota, that focuses on developing fully human polyclonal antibody therapeutics. The company’s proprietary platform, known as Tc Bovine®, uses genetically engineered cattle to generate large quantities of human antibodies tailored to target specific infectious agents or disease-related antigens. This approach is designed to combine the broad-spectrum coverage of polyclonal antibody therapies with the scalability and consistency required for clinical development and commercial use.

The company’s lead programs are directed primarily at infectious diseases.